Provided by Tiger Trade Technology Pte. Ltd.

Incyte

122.54
-1.8300-1.47%
Volume:146.47K
Turnover:17.96M
Market Cap:24.84B
PE:15.61
High:123.44
Open:122.66
Low:121.61
Close:124.37
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.90
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.92
PE(LYR):19.12

Loading ...

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says

MT Newswires Live
·
Jul 30

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Benzinga Earnings
·
Jul 29

Incyte Says Opzelura Cream Approved in EU to Treat Moderate Atopic Dermatitis

MT Newswires Live
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 29

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte : Morgan Stanley Raises Target Price to $119 from $104

THOMSON REUTERS
·
Jul 29

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte price target raised to $119 from $104 at Morgan Stanley

TIPRANKS
·
Jul 29

Incyte says EC approves Opzelura cream for treatment of AD

TIPRANKS
·
Jul 29

Incyte price target raised to $140 from $136 at BofA

TIPRANKS
·
Jul 29

Incyte : H.c. Wainwright Raises Target Price to $150 from $140

THOMSON REUTERS
·
Jul 29

Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

THOMSON REUTERS
·
Jul 29

Incyte Corporation : Barclays Raises Target Price to $139 from $134

THOMSON REUTERS
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), Centene (CNC) and Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte : Guggenheim Raises Target Price to $150 from $136

THOMSON REUTERS
·
Jul 29

Incyte Corp. Stock Advances 9.3%, Outperforms Peers

Dow Jones
·
Jul 29